is crucial for compliance. The primary regulatory authorities for combination products include the Food and Drug Administration (FDA) in the US, the European Medicines Agency (EMA) in the EU, and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

United States

In the US, the FDA regulates combination products under the Food, Drug, and Cosmetic Act (FDCA). The FDA’s Office of Combination Products (OCP) is responsible for coordinating the review of these products, determining their primary mode of action to establish the applicable regulatory pathway. The regulatory pathways include:

• New Drug Application (NDA)
• Abbreviated New Drug Application (ANDA)
• Premarket Approval (PMA)
• 510(k) Pre-market Notification

Guidance documents, such as the FDA’s “Guidance for Industry: How to Determine Whether Your Product Is a Drug, Device, or Biological Product” lay the groundwork for regulatory compliance.

European Union

In the EU, combination products are regulated by multiple directives and regulations, mainly under the Medical Device Regulation (MDR) and the Advanced Therapy Medicinal Products Regulation (ATMP). The classification of combination products in the EU is primarily governed by:

• Directive 2001/83/EC for Medicinal Products
• Regulation (EU) 2017/745 for Medical Devices

Article 1(5) of the MDR specifies products that combine a medicinal product with a device, emphasizing the need for conformity assessment in line with regulatory expectations.

United Kingdom

Post-Brexit, the regulation of combination products in the UK follows the Medicines and Medical Devices Act 2021. The MHRA is responsible for assessing the safety and efficacy of these therapeutic innovations, guided by comparable frameworks to the EU and US systems.

Documentation Requirements

Documentation is a cornerstone of regulatory compliance for combination products. Both FDA and EMA require robust data packages to support the efficacy, safety, and quality of products. Specific documentation elements include:

Common Document Types

• Investigational New Drug Application (IND): Required for human clinical trials in the US.
• Clinical Trial Applications (CTAs): Required for initiating clinical trials in the EU and UK.
• Regulatory Submission Dossier: Comprehensive summary of clinical, preclinical, and manufacturing data.

Quality Management Systems

It is imperative that combination products comply with Good Manufacturing Practice (GMP) regulations. The documentation may include:

• Quality plans and specifications
• Risk management plans
• Post-market surveillance data

Each document must align with applicable guidelines to ensure streamlined regulatory review.

Review/Approval Flow

The review and approval of combination products involve several critical decision points. Understanding the review flow will facilitate timely approvals and reduce the likelihood of regulatory roadblocks.

FDA Review Process

• The initial step is the determination of the combination product designation, which this can be achieved through a Request for Designation (RFD).
• Subsequent submission via the designated pathway (NDA, PMA, 510k) will begin the formal review process.
• On submission, a multidisciplinary team, including experts in CMC, clinical, and labeling, will evaluate the dossier.
• If deficiencies are identified, the FDA will issue a Complete Response Letter (CRL), outlining necessary corrective actions.

EMA and MHRA Review Process

Similar to the FDA, the EMA and MHRA follow sequential review processes, emphasizing collaborative evaluations across different scientific committees aligned with specific types of combination products. Key steps include:

• Pre-submission meetings can provide insights into path objectives and identified risks.
• Submission through the centralised approval process may benefit from streamlined review timelines.
• Responding to questions posed by the authorities quickly can minimize delays in the assessment process.

Common Deficiencies

Awareness of common deficiencies can enhance the likelihood of regulatory success. Regulatory Authorities routinely identify recurrent issues that can lead to delays or non-approvals.

FDA Common Deficiencies

• Insufficient Preclinical Data: Many combination products fail to provide adequate animal studies to support safety.
• Poorly Defined Manufacturing Processes: Lack of in-depth process validation can result in questions during CMC evaluations.
• Clinical Study Design Flaws: Inadequate endpoints or insufficient sample size can lead to negative assessments.

EMA and MHRA Common Deficiencies

• Inconsistent Clinical Data: Variability in data across jurisdictions can raise concerns regarding the robustness of clinical findings.
• Documentation Gaps: Failing to provide thorough and well-formatted documentation can result in administrative delays.
• Risk Management Oversight: Inadequate risk assessment and mitigation strategies may lead to scrutiny from regulators during the approval processes.

RA-Specific Decision Points

Several critical decision points arise throughout the development and regulatory process of combination products. Addressing these early can streamline the approval pathway and may include:

When to File as Variation vs. New Application

• If there is a significant change in formulation or intended use, filing a new application may be necessary.
• Minor modifications may qualify for a variation submission, which is often less resource-intensive and more expedient.

How to Justify Bridging Data

Bridging data become essential when establishing equivalence between existing products and a new combination product. Documenting scientific reasoning, comprehensive studies, and rational arguments will be required to support any assertions of equivalency.

Conclusion

The complex landscape of combination products necessitates thorough knowledge of relevant regulations and an understanding of agency expectations. By adhering to the guidelines of regulatory authorities such as the FDA, EMA, and MHRA, professionals in Regulatory Affairs can navigate the unique challenges presented by combination products. This article outlines essential considerations, including legal bases, necessary documentation, approval processes, common deficiencies, and strategic decision points. Engaging in compliance-oriented practices right from development to post-market can optimize the approval journey and expand therapeutic access to patients.